120 related articles for article (PubMed ID: 35864365)
1. Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?
Gazendam AM; Schneider P; Spiguel A; Ghert M
Ann Surg Oncol; 2022 Nov; 29(12):7312-7317. PubMed ID: 35864365
[TBL] [Abstract][Full Text] [Related]
2. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
[TBL] [Abstract][Full Text] [Related]
3. Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial Data.
Bozzo A; Yeung CM; Van De Sande M; Ghert M; Healey JH;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):65-72. PubMed ID: 37466582
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for All-Cause Early Reoperation Following Tumor Resection and Endoprosthetic Reconstruction: A Secondary Analysis from the PARITY Trial.
Kendal JK; Slawaska-Eng D; Gazendam A; Schneider P; Wessel LE; Ghert M; Bernthal NM;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):4-9. PubMed ID: 37466573
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY): a multi-center randomized controlled study comparing alternative antibiotic regimens in patients undergoing tumor resections with endoprosthetic replacements-a statistical analysis plan.
Schneider P; Heels-Ansdell D; Thabane L; Ghert M;
Trials; 2021 Mar; 22(1):223. PubMed ID: 33752752
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the PARITY Sub-Analysis "Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?".
Zeitlinger L; Randall RL
Ann Surg Oncol; 2022 Nov; 29(12):7237-7238. PubMed ID: 35907989
[No Abstract] [Full Text] [Related]
7. Surgical Duration Is Independently Associated with an Increased Risk of Surgical Site Infection and May Not Be Mitigated by Prolonged Antibiotics: A Secondary Analysis of the PARITY Trial of Infection After Lower-Extremity Endoprosthetic Reconstruction for Bone Tumors.
Zeitlinger L; Wilson M; Randall RL; Thorpe S;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):79-86. PubMed ID: 37466584
[TBL] [Abstract][Full Text] [Related]
8. Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
Asavamongkolkul A; Waikakul S; Phimolsarnti R; Kiatisevi P; Wangsaturaka P
J Med Assoc Thai; 2007 Apr; 90(4):706-17. PubMed ID: 17487125
[TBL] [Abstract][Full Text] [Related]
9. Patient and Surgical Risk Factors for Surgical Site Infection in Lower-Extremity Oncological Endoprosthetic Reconstruction: A Secondary Analysis of the PARITY Trial Data.
Slawaska-Eng D; Gazendam AM; Kendal J; Schneider P; Becker RG; Freitas JP; Bernthal N; Ghert M;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):41-48. PubMed ID: 37466579
[TBL] [Abstract][Full Text] [Related]
10. Surgical Site Infection Is Not Associated with 1-Year Progression-Free Survival After Endoprosthetic Reconstruction for Lower-Extremity Osteosarcoma: A Secondary Analysis of PARITY Study Data.
Jackson KJ; Sullivan CD; Zimel MN; Wustrack RL;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):49-56. PubMed ID: 37466580
[TBL] [Abstract][Full Text] [Related]
11. Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?
Malik AT; Alexander JH; Mayerson JL; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Oct; 478(10):2284-2295. PubMed ID: 32667758
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Functional Recovery among Musculoskeletal Oncology Patients Undergoing Lower Extremity Endoprosthetic Reconstruction.
Gazendam AM; Schneider P; Heels-Ansdell D; Bhandari M; Busse JW; Ghert M
Curr Oncol; 2022 Oct; 29(10):7598-7606. PubMed ID: 36290877
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
; Ghert M; Schneider P; Guyatt G; Thabane L; Vélez R; O'Shea T; Randall RL; Turcotte R; Wilson D; Wunder JS; Baptista AM; Cheng EY; Doung YC; Ferguson PC; Giglio V; Hayden J; Heels-Ansdell D; Khan SA; Sampath Kumar V; McKay P; Miller B; van de Sande M; Zumárraga JP; Bhandari M
JAMA Oncol; 2022 Mar; 8(3):345-353. PubMed ID: 34989778
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy and Nipple-Sparing Mastectomy: Timing and Postoperative Complications.
Bartholomew AJ; Dervishaj OA; Sosin M; Kerivan LT; Tung SS; Caragacianu DL; Willey SC; Tousimis EA
Ann Surg Oncol; 2019 Sep; 26(9):2768-2772. PubMed ID: 31123933
[TBL] [Abstract][Full Text] [Related]
15. Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients.
Müller C; Winter CC; Rosenbaum D; Boos J; Gosheger G; Hardes J; Vieth V
BMC Musculoskelet Disord; 2010 Dec; 11():287. PubMed ID: 21190557
[TBL] [Abstract][Full Text] [Related]
16. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
[TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.
van der Woude HJ; Bloem JL; Verstraete KL; Taminiau AH; Nooy MA; Hogendoorn PC
AJR Am J Roentgenol; 1995 Sep; 165(3):593-8. PubMed ID: 7645476
[TBL] [Abstract][Full Text] [Related]
18. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
Jooya ND; Ciccone MA; Brunette LL; Pham HQ; Yessaian AA; Muderspach LI; Roman LD; Matsuo K
Gynecol Oncol; 2022 Jun; 165(3):428-436. PubMed ID: 35459549
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
20. [Pre- and postoperative chemotherapy in bone and soft tissue tumors].
Höffken K
Langenbecks Arch Chir; 1987; 372():311-4. PubMed ID: 3481009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
